# Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

> **NCT00589784** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- CNS Cancer
- Meningioma
- Intracranial Hemangiopericytoma
- Hemangioblastoma
- Neurofibromatosis

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00589784
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-01-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00589784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00589784, "Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00589784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*